Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like U*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000090 UCB, Inc 03/31/2020 50474087015 BRIVIACT CV 10 MG/ML, 300ML ORAL SOLUTION 01/01/2020 34.35 1179.35 02/21/2021 Single Source Drug 190230000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474077009 BRIVIACT CV 100 MG, 100 UNIT DOSE TABLETS 01/01/2020 57.25 1965.59 02/21/2021 Single Source Drug 190230000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474077066 BRIVIACT CV 100 MG, 60 TABLETS 01/01/2020 34.35 1179.35 02/21/2021 Single Source Drug 190230000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474037066 BRIVIACT CV 10MG, 60 TABLETS 01/01/2020 34.35 1179.35 02/21/2021 Single Source Drug 190230000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474047009 BRIVIACT CV 25MG, 100 UNIT DOSE TABLETS 01/01/2020 57.25 1965.59 02/21/2021 Single Source Drug 190230000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474047066 BRIVIACT CV 25MG, 60 TABLETS 01/01/2020 34.35 1179.35 02/21/2021 Single Source Drug 190230000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474057066 BRIVIACT CV 50MG, 60 TABLETS 01/01/2020 34.35 1179.35 02/21/2021 Single Source Drug 190230000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474057009 BRIVIACT CV 5OMG, 100 UNIT DOSE TABLETS 01/01/2020 57.25 1965.59 02/21/2021 Single Source Drug 190230000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474067066 BRIVIACT CV 75MG, 60 TABLETS 01/01/2020 34.35 1179.35 02/21/2021 Single Source Drug 190230000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474097075 BRIVIACT INJECTION FOR INTRAVENOUS USE, CV 50 MG/5ML, 10 VIALS 01/01/2020 14.71 505.43 02/21/2021 Single Source Drug 190230000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474070062 CIMZIA LYOPHOLIZED POWDER FOR INJECTION, 2 X 200 MG VIALS 01/01/2020 302.92 4630.35 02/13/2024 Single Source Drug 1217472000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474071079 CIMZIA PRE-FILLED SYRINGE KIT, 2 X 200 MG/ML PRE-FILLED SYRINGES 01/01/2020 302.92 4630.35 02/13/2024 Single Source Drug 1217472000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474071081 CIMZIA PRE-FILLED SYRINGE STARTER KIT, 6 X 200 MG/ML PRE-FILLED SYRINGES 01/01/2020 908.75 13891.04 02/13/2024 Single Source Drug 1217472000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474080103 NEUPRO 1 MG, 30 PATCHES 01/01/2020 32.95 705.43 12/22/2030 Single Source Drug 108543000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474080203 NEUPRO 2 MG, 30 PATCHES 01/01/2020 32.95 705.43 12/22/2030 Single Source Drug 108543000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474080303 NEUPRO 3 MG, 30 PATCHES 01/01/2020 32.95 705.43 12/22/2030 Single Source Drug 108543000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474080403 NEUPRO 4 MG, 30 PATCHES 01/01/2020 32.95 705.43 12/22/2030 Single Source Drug 108543000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474080503 NEUPRO 6 MG, 30 PATCHES 01/01/2020 32.95 705.43 12/22/2030 Single Source Drug 108543000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 50474080603 NEUPRO 8 MG, 30 PATCHES 01/01/2020 32.95 705.43 12/22/2030 Single Source Drug 108543000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 00131247835 VIMPAT CV 100MG, 60 TABLETS 01/01/2020 25.92 890.25 03/17/2022 Single Source Drug 1120119000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 00131247860 VIMPAT CV 100MG, 60 UNIT DOSE TABLETS 01/01/2020 28.52 979.35 03/17/2022 Single Source Drug 1120119000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 00131541071 VIMPAT CV 10MG/ML ORAL SOLUTION, 200 ML 01/01/2020 10.72 368.30 03/17/2022 Single Source Drug 1120119000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 00131541070 VIMPAT CV 10MG/ML ORAL SOLUTION, 465 ML 01/01/2020 21.45 736.59 03/17/2022 Single Source Drug 1120119000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 00131247935 VIMPAT CV 150MG, 60 TABLETS 01/01/2020 27.46 942.85 03/17/2022 Single Source Drug 1120119000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 00131247960 VIMPAT CV 150MG, 60 UNIT DOSE TABLETS 01/01/2020 30.22 1037.19 03/17/2022 Single Source Drug 1120119000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 00131248035 VIMPAT CV 200MG, 60 TABLETS 01/01/2020 27.46 943.11 03/17/2022 Single Source Drug 1120119000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 00131248060 VIMPAT CV 200MG, 60 UNIT DOSE TABLETS 01/01/2020 30.22 1037.52 03/17/2022 Single Source Drug 1120119000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 00131247735 VIMPAT CV 50MG, 60 TABLETS 01/01/2020 16.58 569.43 03/17/2022 Single Source Drug 1120119000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 00131247760 VIMPAT CV 50MG, 60 UNIT DOSE TABLETS 01/01/2020 18.23 626.43 03/17/2022 Single Source Drug 1120119000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090 UCB, Inc 03/31/2020 00131181067 VIMPAT INJECTION FOR INTRAVENOUS USE, CV 200MG/20ML, 10 VIALS 01/01/2020 22.68 778.94 03/17/2022 Single Source Drug 1120119000 None None 1 The price increases are not necessitated by a change or improvement in the drugs. None None None None None None None None None None None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000036 United Therapeutics 09/30/2020 66302020603 "Tyvaso 1.74 mg Inhalation 2.9 mL/ampule *4" 07/01/2020 111.42 2587.32 05/14/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036 United Therapeutics 09/30/2020 66302020604 "Tyvaso 1.74 mg Inhalation 2.9 mL/ampule*4" 07/01/2020 201.54 4680.17 05/14/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036 United Therapeutics 09/30/2020 66302020602 "Tyvaso Refill kit 1.74 mg Inhalation 2.9 mL/ampule * 28" 07/01/2020 779.91 18111.22 05/14/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036 United Therapeutics 09/30/2020 66302020601 "Tyvaso Starter kit 1.74 mg Inhalation 2.9 mL/ampule * 28" 07/01/2020 870.03 20204.08 05/14/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036 United Therapeutics 09/30/2020 66302001401 "Unituxin 17.5mg/5 ML Injection/vial 5ml Vial" 08/15/2020 401.77 11880.77 03/01/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036 United Therapeutics 03/31/2020 66302001401 Unituxin Dinutuximab; 17.5mg/5mL; Injection/vial; 5mL vial 01/01/2020 639.50 11479.00 03/01/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Unit sales data- This information is confidential and proprietary, and not publicly available or within the public domain. Cost increase factors- This information was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain. Change/Improvement description- This information was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain. Acquisition fields have not been completed because the product was not acquired from another manufacturer within the last 5 years
Rx0000161 Upsher-Smith Laboratories, LLC 03/31/2020 00245107430 Qudexy XR 100mg Cpsl Btl 30 01/31/2020 37.06 654.75 03/19/2033 Single Source Drug None 1 None 1 No change or improvement None None None None None None None None None None None Product not acquired so data not provided in the acquisition-related fields
Rx0000161 Upsher-Smith Laboratories, LLC 03/31/2020 00245107530 Qudexy XR 150mg Cpsl Btl 30 01/31/2020 45.59 805.38 03/19/2033 Single Source Drug None 1 None 1 No change or improvement None None None None None None None None None None None Product not acquired so data not provided in the acquisition-related fields
Rx0000161 Upsher-Smith Laboratories, LLC 03/31/2020 00245107330 Qudexy XR 200mg Cpsl Btl 30 01/31/2020 50.70 895.67 03/19/2033 Single Source Drug None 1 None 1 No change or improvement None None None None None None None None None None None Product not acquired so data not provided in the acquisition-related fields
Rx0000161 Upsher-Smith Laboratories, LLC 03/31/2020 00245107130 Qudexy XR 25mg Cpsl Btl 30 01/31/2020 14.36 253.70 03/19/2033 Single Source Drug None 1 None 1 No change or improvement None None None None None None None None None None None Product not acquired so data not provided in the acquisition-related fields
Rx0000161 Upsher-Smith Laboratories, LLC 03/31/2020 00245107230 Qudexy XR 50mg Cpsl Btl 30 01/31/2020 18.71 330.47 03/19/2033 Single Source Drug None 1 None 1 No change or improvement None None None None None None None None None None None Product not acquired so data not provided in the acquisition-related fields
Rx0000161 Upsher-Smith Laboratories, LLC 03/31/2020 00832107430 Topiramate ER 100mg Cpsl Btl 30 01/31/2020 30.22 533.91 03/19/2033 Single Source Drug None 1 None 1 No change or improvement None None None None None None None None None None None Product not acquired so data not provided in the acquisition-related fields Drug is a single source drug as it is the authorized generic to Qudexy XR
Rx0000161 Upsher-Smith Laboratories, LLC 03/31/2020 00832107530 Topiramate ER 150mg Cpsl Btl 30 01/31/2020 37.17 656.72 03/19/2033 Single Source Drug None 1 None 1 No change or improvement None None None None None None None None None None None Product not acquired so data not provided in the acquisition-related fields Drug is a single source drug as it is the authorized generic to Qudexy XR
Rx0000161 Upsher-Smith Laboratories, LLC 03/31/2020 00832107330 Topiramate ER 200mg Cpsl Btl 30 01/31/2020 41.34 730.38 03/19/2033 Single Source Drug None 1 None 1 No change or improvement None None None None None None None None None None None Product not acquired so data not provided in the acquisition-related fields Drug is a single source drug as it is the authorized generic to Qudexy XR
Rx0000161 Upsher-Smith Laboratories, LLC 03/31/2020 00832107130 Topiramate ER 25mg Cpsl Btl 30 01/31/2020 11.71 206.89 03/19/2033 Single Source Drug None 1 None 1 No change or improvement None None None None None None None None None None None Product not acquired so data not provided in the acquisition-related fields Drug is a single source drug as it is the authorized generic to Qudexy XR
Rx0000161 Upsher-Smith Laboratories, LLC 03/31/2020 00832107230 Topiramate ER 50mg Cpsl Btl 30 01/31/2020 15.25 269.48 03/19/2033 Single Source Drug None 1 None 1 No change or improvement None None None None None None None None None None None Product not acquired so data not provided in the acquisition-related fields Drug is a single source drug as it is the authorized generic to Qudexy XR